je.st
news
Tag: merck
United Bank VA Has $2,334,000 Position in Merck & Co., Inc.
2016-03-02 05:07:29| Biotech - Topix.net
United Bank VA decreased its stake in Merck & Co., Inc. by 14.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 44,185 shares of the company's stock after selling 7,199 shares during the period.
Tags: inc
united
position
bank
Merck Animal Health awards scholarships to swine veterinary students
2016-02-29 06:00:00| National Hog Farmer
In partnership with the American Association of Swine Veterinarians Foundation — the charitable arm of the American Association of Swine Veterinarians — Merck Animal Health today announced the 2016 recipients of the AASVF/Merck Animal Health Veterinary Student Scholarships. read more
Tags: health
students
awards
animal
Merck Announces Second-Quarter 2016 Dividend
2016-02-23 19:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the companys common stock for the second quarter of 2016. Payment will be made on April 7, 2016, to shareholders of record at the close of business on March 15, 2016. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces dividend
R. M. Davis Decreases Stake in Merck & Co., Inc.
2016-02-21 08:48:41| Biotech - Topix.net
R. M. Davis lowered its stake in Merck & Co., Inc. by 7.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,288 shares of the company's stock after selling 1,852 shares during the period.
Tags: inc
davis
decreases
stake
Merck Receives Complete Response Letter from the U.S. FDA for ZETIA (ezetimibe) and VYTORIN (ezetimibe and simvastatin)
2016-02-15 23:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA and VYTORIN for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Amy Klug, 908-740-1898orTeri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: complete
response
letter
receives
Sites : [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] next »